Prof. Luca Gallelli
Department of Health Science, University Magna Craecia, Catanzaro, Calabria, Italy
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
28Years (1999-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications8 March 2015 in Expert Review of Anti-infective Therapy
Journal Article
Raffaele SerraRGRaffaele Grande
Raffaele GrandeLBLucia Butrico
Lucia Butrico
ARAlessio Rossi
Alessio Rossi
USUgo Francesco Settimio
Ugo Francesco Settimio
SFStefano de Franciscis
Stefano de Franciscis +3
Chronic leg ulcers affect 1-2% of the general population and are related to increased morbidity and health costs. Staphylococcus aureus and Pseudomonas aeruginosa are the most common bacteria isolated from chronic wounds. They can express virulence factors and surface proteins affecting wound healing. The co-infection of S. aureus and P. aeruginosa is more virulent than single infection. In particular, S. aureus and P. aeruginosa have both intrinsic and acquired antibiotic resistance, making clinical management of infection a real challenge, particularly in patients with comorbidity. Therefore, a correct and prompt diagnosis of chronic wound infection requires a detailed knowledge of skin bacterial flora. This is a necessary prerequisite for tailored pharmacological treatment, improving symptoms, and reducing side effects and antibiotic resistance.
Journal Article
Erika CioneCTChiara La Torre
Chiara La Torre
Roberto CannataroMCMaria Cristina Caroleo
Maria Cristina Caroleo
Pierluigi PlastinaLuca GallelliEpidemiologic studies suggest that dietary polyphenol intake is associated with a lower incidence of several non-communicable diseases. Although several foods contain complex mixtures of polyphenols, numerous factors can affect their content. Besides the well-known capability of these molecules to act as antioxidants, they are able to interact with cell-signaling pathways, modulating gene expression, influencing the activity of transcription factors, and modulating microRNAs. Here we deeply describe four polyphenols used as nutritional supplements: quercetin, resveratrol, epigallocatechin gallate (ECGC), and curcumin, summarizing the current knowledge about them, spanning from dietary sources to the epigenetic capabilities of these compounds on microRNA modulation.
1 January 2015 in Mediators of Inflammation
Journal Article
GPGirolamo Pelaia
Girolamo Pelaia
Alessandro VatrellaMBMaria Teresa Busceti
Maria Teresa Busceti
Luca GallelliCCCecilia Calabrese
Cecilia CalabreseRMRosario Maselli
Rosario Maselli +1
Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the whole spectrum of asthma severity, ranging from mild‐to‐moderate to severe uncontrolled disease, whereas neutrophilic inflammation occurs mostly in more severe asthma. Eosinophilic asthma includes either allergic or nonallergic phenotypes underlying immune responses mediated by T helper (Th)2 cell‐derived cytokines, whilst neutrophilic asthma is mostly dependent on Th17 cell‐induced mechanisms. These immune‐inflammatory profiles develop as a consequence of a functional impairment of T regulatory (Treg) lymphocytes, which promotes the activation of dendritic cells directing the differentiation of distinct Th cell subsets. The recent advances in the knowledge of the cellular and molecular mechanisms underlying asthmatic inflammation are contributing to the identification of novel therapeutic targets, potentially suitable for the implementation of future improvements in antiasthma pharmacologic treatments.
1 July 2013
Journal Article
CPCaterina Palleria
Caterina Palleria
APAntonello Di Paolo
Antonello Di Paolo
CGChiara Giofrè
Chiara Giofrè
CCChiara Caglioti
Chiara Caglioti
GLGiacomo Leuzzi
Giacomo Leuzzi
Luca Gallelli +2
Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%. In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy. DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic. In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.
1 September 2019 in Drug Design, Development and Therapy
Journal Article
Luca GallelliThis review discusses historical and recent pharmacological and clinical data on the anti-edematous, anti-inflammatory, and venotonic properties of escin (Reparil®). Escin, the active component of Aesculus hippocastanum, or horse chestnut, is available as orally absorbable dragées and as a transdermal gel. The anti-inflammatory and anti-edematous effects of escin have been studied over many years in pre-clinical models. More recent data confirm the anti-inflammatory properties of escin in reducing vascular permeability in inflamed tissues, thereby inhibiting edema formation. The venotonic effects of escin have been demonstrated primarily by in vitro studies of isolated human saphenous veins. The ability of escin to prevent hypoxia-induced disruption to the normal expression and distribution of platelet endothelial cell-adhesion molecule-1 may help explain its protective effect on blood vessel permeability. Escin oral dragées and transdermal gel have both demonstrated efficacy in blunt trauma injuries and in chronic venous insufficiency. Both oral escin and the transdermal gel are well tolerated.
26 March 2013 in Wound Repair and Regeneration
Journal Article
Raffaele SerraGBGianluca Buffone
Gianluca BuffoneDFDaniela Falcone
Daniela Falcone
VMVincenzo Molinari
Vincenzo Molinari
MSMonica Scaramuzzino
Monica Scaramuzzino
SFStefano de Franciscis
Stefano de Franciscis +1
About Me
Last Name: GALLELLI
First Name(s): LUCA
Title: PROF
Date of birth: 3 NOVEMBER 1973
Place of birth: NAPLES
ORCID ID 0000-0003-0858-7902
Researcher ID A-5180-2011
Scopus author number: 6602177838
RESEARCH ACTIVITIES: Winner of five research awards (SIF Research Fellowship; First Runner-Up Start-CUP Calabria 2016; Special Rubino Award 2016; First Runner-Up Equal Opportunity Special Mention 2016; First Runner-Up National Innovation Award 2017); twice winner of public funding on a competitive basis; one first phase Horizon2020 SME Instrument1 Funding of MIUR research base activities 2017; winner of funding from Private Companies for two research projects. Principal investigator in 31 clinical trials; responsible for 26 congresses with CME credits; 257 English-language extenso publications on Scopus (h-Index 48). Published four book chapters and contributed to congresses.
ADDITIONAL ACTIVITIES: Tenured lecturer in Pharmacology for various undergraduate courses: Medicine, Technicians and Master Biotechnology of the University of Catanzaro. Contracted to teach Pharmacology in the Schools of Specialization of Nephrology, Pharmacology, Diseases of the Respiratory System, Forensic Medicine of the University of Catanzaro. Lecturer-specific training course in General Medicine, Region of Calabria triennium 2017/20 ASSISTANCE ACTIVITIES. Medical Director at UO Clinical Pharmacology AOU Mater Domini CatanzaroTERZA MISSION. Six national patents, two with international extension.